

# ADLER & ASSOCIATES

P.O. BOX 710509 HOUSTON, TEXAS 77271-0509

WRITER'S DIRECT DIAL (713) 270-5391 WRITER'S DIRECT FACS. (713)-270-5361 E. MAIL: BADLER1@houston.rr.com INTELLECTUAL PROPERTY LAW (PATENT, BIOTECHNOLOGY, COMPUTER, TRADEMARK & TRADE SECRET LAW)

October 30, 2003

Docket No.: D6219CIP

MS PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith for filing is the continuation-in-part patent application which claims benefit of priority under 35 U.S.C 120 of U.S. Serial No. 09/569,789, filed May 12, 2000, which claims benefit of priority under 35 U.S.C. 119(e) of USSN 60/133,634, filed May 12, 1999, now abandoned in the:

Name of: Curiel, et al.

> For: Infectivity-Enhanced Conditionally- Replicative Adenovirus And Uses Thereof

### **CLAIMS AS FILED**

Fee for:	Small entity	Amount
Basic fee	\$385	\$385
Each independent claim		
in excess of 3 (0)	\$ 4 3	\$ 0
Each claim excess of 20 (4)	\$ 9	\$ 36
Multiple dependent claim		
TOTA	L FILING FEE	\$421

X Please charge my Deposit Account No. 07-1185 in the total amount of the filing fee and the assignment recordation fee if any.

X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1185.

- X Any additional fees under 37 CFR 1.16.
- X Any application processing fees under 37 CFR 1.17.

## X Small Entity Statement

Applicants hereby claim small entity status under 37 CFR 1.27(d).

#### X Relate Back--35 U.S.C. 120

This continuation-in-part application claims benefit of priority under 35 U.S.C 120 of U.S. Serial No. 09/569,789, filed May 12, 2000, which claims benefit of priority under 35 U.S.C. 119(e) of USSN 60/133,634, filed May 12, 1999, now abandoned.

\_\_\_ Assignment

The application is assigned by the inventors to the

### X Sequence Listing

The sequence listing is enclosed, including a paper copy, a copy on disk for the computer readable form and a compliance letter indicating that the sequence listing on the paper copy and the disk are one and the same.

## X Drawings

Figures 1A-1B, 2, 3A-3B, 4A-4C, 5A-5B, 6A-6B, 7-13, 14A-14B, 15-16, 17A-17B, 18, 19A-19B, 20A-20C, 21-23, 24A-24B, 25-27, 28A-28B, and 29-35 are enclosed herewith on 34 sheets.

# X Power of Attorney

X is attached.

X Address all future communications to:

Benjamin Aaron Adler ADLER & ASSOCIATES 8011 Candle Lane Houston TX 77071 (713) 777-2321 BADLER1@houston.rr.com

X\_ Two photocopies of this sheet are enclosed.

Date: Oct 30, 2003

Benjamin Aaron Adler, Ph.D., J.D.

Counsel for Applicant Registration No. 35,423

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Curiel et al. § ART UNIT:

FILED: October 30, 2003 § EXAMINER:

SERIAL NO.: 

\$
8

FOR: Infectivity-Enhanced Conditionally-§ DOCKET:

Replicative Adenovirus And Uses § D6219CIP

Thereof

MS PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### **CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

Dear Sir:

I hereby certify that the following documents, which are attached, are being deposited, under 37 CFR 1.10, with the United States Postal Service "Express Mail Post Office to Addressee" service as Express Mail No. EV330326636US in an envelope addressed to: MS PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

- 1) Continuation-in-part application + 34 sheets of drawings;
- 2) Transmittal Letter;
- 3) Sequence Listing; Compliance Statement, & CRF;
- 4) Four (4) Combined Declarations and Powers of Attorney;
- 5) Fig. 1A-1B, 2, 3A-3B, 4A-4C, 5A-5B, 6A-6B, 7-13, 14A-14B, 15-16, 17A-17B, 18, 19A-19B, 20A-20C, 21-23, 24A-24B, 25-27, 28A-28B, and 29-35; and
- 6) Return postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

ADLER & ASSOCIATES

8011 Candle Lane

Houston, Texas 77071 (713) 270-5391

badler1@houston.rr.com

Benjamin Aaron Adler, Ph.D., J.D.

Counsel for Applicant Registration No. 35,423